Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ISRCTN91975924) titled 'A clinical trial to assess whether a self-amplifying ribonucleic acid (saRNA) vaccine against Rabies viruses is safe and induces immune responses' on May 22.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Dose comparison
Assignment: Single
Purpose: Prevention
Primary Sponsor: Imperial College London
Condition:
Rabies
Infections and Infestations
Intervention:
RAB-Vac is a single-blinded, randomised Phase I trial using the online tool "sealed envelope" to generate randomisation lists. Healthy participants aged 18-50 years will be enroll...